Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transitioning Therapy From Alendronate to Denosumab in Postmenopausal Women With Low Bone Mineral Density
2006-000849-19Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of denosumab in postmenopausal osteoporosis and osteopenia (2 arms), sponsored by Amgen. Primary endpoint: Percent change in total hip bone mineral density from baseline to 12 months. Started Aug 2006; status: completed.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosisosteopenia
Beyond the preview
Go deeper on 2006-000849-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000849-19.